| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
|
Pabinger, Ingrid
|
|
2018
|
|
7 |
p. e289-e298
|
article
|
| 2 |
Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes
|
Gavillet, Mathilde
|
|
|
|
7 |
p. e534
|
article
|
| 3 |
Addressing bias towards patients with sickle cell disease
|
DeLaune, Jess
|
|
|
|
7 |
p. e508
|
article
|
| 4 |
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases
|
Chan, Kwok Ying
|
|
|
|
7 |
p. e473-e474
|
article
|
| 5 |
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
|
Eapen, Mary
|
|
2017
|
|
7 |
p. e325-e333
nvt p.
|
article
|
| 6 |
American Society of Clinical Oncology Annual Meeting 2019
|
del Pozo Martín, Yaiza
|
|
2019
|
|
7 |
p. e349
|
article
|
| 7 |
A new option for treating CKD-associated anaemia in children
|
The Lancet Haematology,
|
|
2018
|
|
7 |
p. e270
|
article
|
| 8 |
Anti-thymocyte globulin for GVHD: one dose does not fit all
|
Admiraal, Rick
|
|
|
|
7 |
p. e505
|
article
|
| 9 |
A painful path to transparency
|
The Lancet Haematology,
|
|
2019
|
|
7 |
p. e338
|
article
|
| 10 |
2020 ASCO Annual Meeting
|
Cookson, Emma
|
|
|
|
7 |
p. e507
|
article
|
| 11 |
Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort study
|
Miles, Lachlan F
|
|
|
|
7 |
p. e514-e522
|
article
|
| 12 |
Black lives matter in haematology
|
The Lancet Haematology,
|
|
|
|
7 |
p. e499
|
article
|
| 13 |
Blood group genotyping: faster and more reliable identification of rare blood for transfusion
|
Sandler, S Gerald
|
|
2015
|
|
7 |
p. e270-e271
nvt p.
|
article
|
| 14 |
Building consensus: steps toward standardised haemovigilance reporting
|
Roubinian, Nareg
|
|
2019
|
|
7 |
p. e339-e340
|
article
|
| 15 |
Burnout in the haematological workforce
|
The Lancet Haematology,
|
|
|
|
7 |
p. e477
|
article
|
| 16 |
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia
|
Short, Nicholas J
|
|
|
|
7 |
p. e535-e545
|
article
|
| 17 |
Climate change and haematology: perspectives from the Philippines
|
Ong, Bradley Ashley G
|
|
|
|
7 |
p. e468-e469
|
article
|
| 18 |
Concerns on perioperative anaemia management in the FIT trial
|
Sato, Tomohiko
|
|
|
|
7 |
p. e485-e486
|
article
|
| 19 |
Concerns on perioperative anaemia management in the FIT trial
|
Petzer, Verena
|
|
|
|
7 |
p. e485
|
article
|
| 20 |
Consensus recommendations for improvement of unmet clinical needs—the example of chronic graft-versus-host disease: a systematic review and meta-analysis
|
Olivieri, Jacopo
|
|
2015
|
|
7 |
p. e297-e305
nvt p.
|
article
|
| 21 |
Correction to Lancet Haematol 2022; 9: e200–07
|
|
|
|
|
7 |
p. e475
|
article
|
| 22 |
Correction to Lancet Haematol 2019; 6: e366–74
|
|
|
2019
|
|
7 |
p. e348
|
article
|
| 23 |
Correction to Lancet Haematol 2023; 10: e213–24
|
|
|
|
|
7 |
p. e490
|
article
|
| 24 |
Correction to Lancet Haematol 2023; 10: e433–44
|
|
|
|
|
7 |
p. e490
|
article
|
| 25 |
Correction to Lancet Haematol 2023; 10: e333–45
|
|
|
|
|
7 |
p. e490
|
article
|
| 26 |
Could improving mental health disorders help increase cancer survival?
|
Davies, Elizabeth A
|
|
|
|
7 |
p. e482-e484
|
article
|
| 27 |
Counting the carbon cost of heparin: an evolving tragedy of the commons?
|
Fan, Bingwen Eugene
|
|
|
|
7 |
p. e469-e471
|
article
|
| 28 |
Counting the cost of cancer treatment
|
The Lancet Haematology,
|
|
2015
|
|
7 |
p. e267-
1 p.
|
article
|
| 29 |
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|
Leentjens, Jenneke
|
|
|
|
7 |
p. e524-e533
|
article
|
| 30 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
|
Thomas, Xavier
|
|
|
|
7 |
p. e468-e469
|
article
|
| 31 |
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
|
Muus, Petra
|
|
|
|
7 |
p. e481-e482
|
article
|
| 32 |
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
|
Peterlin, Pierre
|
|
|
|
7 |
p. e521-e529
|
article
|
| 33 |
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
|
Lancet, Jeffrey E
|
|
|
|
7 |
p. e481-e491
|
article
|
| 34 |
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
|
Hunger, Stephen P
|
|
|
|
7 |
p. e510-e520
|
article
|
| 35 |
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
|
Clark, Richard E
|
|
2017
|
|
7 |
p. e310-e316
nvt p.
|
article
|
| 36 |
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
|
Clark, Richard E
|
|
2019
|
|
7 |
p. e375-e383
|
article
|
| 37 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome
|
Shibusawa, Motoharu
|
|
|
|
7 |
p. e487-e488
|
article
|
| 38 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome
|
Halder, Rohan
|
|
|
|
7 |
p. e487
|
article
|
| 39 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome – Authors' reply
|
Grupp, Stephan A
|
|
|
|
7 |
p. e488-e489
|
article
|
| 40 |
Direct oral anticoagulants and obesity: one size fits all?
|
den Exter, Paul L
|
|
2019
|
|
7 |
p. e341-e342
|
article
|
| 41 |
Do big numbers assure high-quality of data?
|
Crocetti, Emanuele
|
|
2017
|
|
7 |
p. e309-
1 p.
|
article
|
| 42 |
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
|
Ryu, Yun Kyoung
|
|
|
|
7 |
p. e463-e465
|
article
|
| 43 |
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
|
Kushnir, Margarita
|
|
2019
|
|
7 |
p. e359-e365
|
article
|
| 44 |
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial
|
Johnston, Patrick B
|
|
2016
|
|
7 |
p. e309-e316
nvt p.
|
article
|
| 45 |
Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
|
George, Lindsey A
|
|
|
|
7 |
p. e465-e466
|
article
|
| 46 |
First, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation
|
Perram, Jacinta
|
|
|
|
7 |
p. e476-e477
|
article
|
| 47 |
Giving hereditary haemorrhagic telangiectasia the attention it deserves
|
Al-Samkari, Hanny
|
|
|
|
7 |
p. e472-e474
|
article
|
| 48 |
High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed
|
Bridoux, Frank
|
|
2019
|
|
7 |
p. e347
|
article
|
| 49 |
How to define treatment failure for JAK inhibitors
|
Kvasnicka, Hans Michael
|
|
2017
|
|
7 |
p. e305-e306
nvt p.
|
article
|
| 50 |
Hyper-CVAD: a regimen for all seasons
|
Seftel, Matthew D
|
|
|
|
7 |
p. e501-e502
|
article
|
| 51 |
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
|
Jabbour, Elias
|
|
|
|
7 |
p. e523-e533
|
article
|
| 52 |
“I can't breathe”: how sickle cell disease manifests in the USA today
|
Zaidi, Ahmar U
|
|
|
|
7 |
p. e479-e480
|
article
|
| 53 |
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis
|
Campbell, Christine M
|
|
|
|
7 |
p. e546
|
article
|
| 54 |
Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study
|
Nnodu, Obiageli E
|
|
|
|
7 |
p. e534-e540
|
article
|
| 55 |
Improved survival with salvage autologous stem-cell transplantation in myeloma
|
Holstein, Sarah A
|
|
2016
|
|
7 |
p. e306-e307
nvt p.
|
article
|
| 56 |
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians
|
Gurnari, Carmelo
|
|
|
|
7 |
p. e492-e494
|
article
|
| 57 |
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial
|
Delaney, Colleen
|
|
2016
|
|
7 |
p. e330-e339
nvt p.
|
article
|
| 58 |
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma
|
O’Donnell, Jake S
|
|
|
|
7 |
p. e539-e548
|
article
|
| 59 |
Integration of red cell genotyping into the blood supply chain: a population-based study
|
Flegel, Willy A
|
|
2015
|
|
7 |
p. e282-e288
nvt p.
|
article
|
| 60 |
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
|
Döhner, Hartmut
|
|
|
|
7 |
p. e495-e509
|
article
|
| 61 |
Intravenous iron in post-bariatric abdominoplasty anaemia: a pragmatic approach
|
Khalafallah, Alhossain A
|
|
2018
|
|
7 |
p. e277-e278
|
article
|
| 62 |
Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil
|
Montano-Pedroso, Juan Carlos
|
|
2018
|
|
7 |
p. e310-e320
|
article
|
| 63 |
Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study
|
Leuraud, Klervi
|
|
2015
|
|
7 |
p. e276-e281
nvt p.
|
article
|
| 64 |
Iron deficiency: effects beyond anaemia?
|
Choorapoikayil, Suma
|
|
|
|
7 |
p. e466-e468
|
article
|
| 65 |
Iron preparations for iron deficiency anaemia in pregnancy: which treatment is best?
|
Shand, Antonia W
|
|
|
|
7 |
p. e471-e472
|
article
|
| 66 |
Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis
|
Rogozińska, Ewelina
|
|
|
|
7 |
p. e503-e512
|
article
|
| 67 |
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
|
Harrison, Claire N
|
|
2017
|
|
7 |
p. e317-e324
nvt p.
|
article
|
| 68 |
Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting
|
Ruiz-Argüelles, Guillermo J
|
|
|
|
7 |
p. e509-e510
|
article
|
| 69 |
Lessons to learn for clinical trials
|
The Lancet Haematology,
|
|
|
|
7 |
p. e499
|
article
|
| 70 |
Long-term efficacy and safety of ruxolitinib in polycythaemia vera
|
Shibusawa, Motoharu
|
|
|
|
7 |
p. e505-e506
|
article
|
| 71 |
Long-term efficacy and safety of ruxolitinib in polycythaemia vera – Authors' reply
|
Kiladjian, Jean-Jacques
|
|
|
|
7 |
p. e506
|
article
|
| 72 |
Machine learning in haematological malignancies
|
Radakovich, Nathan
|
|
|
|
7 |
p. e541-e550
|
article
|
| 73 |
Maintenance therapy in CLL: resolving the controversy
|
Tam, Constantine S
|
|
2016
|
|
7 |
p. e304-e305
nvt p.
|
article
|
| 74 |
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study
|
Kuczmarski, Thomas M
|
|
|
|
7 |
p. e530-e538
|
article
|
| 75 |
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study
|
Rawstron, Andy C
|
|
2017
|
|
7 |
p. e334-e340
nvt p.
|
article
|
| 76 |
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?
|
Semenzato, Gianpietro
|
|
|
|
7 |
p. e549-e556
|
article
|
| 77 |
More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia
|
Murphy, Lindsey
|
|
|
|
7 |
p. e479-e481
|
article
|
| 78 |
mTOR inhibition in diffuse large B-cell lymphoma: new hope?
|
Hess, Georg
|
|
2016
|
|
7 |
p. e302-e303
nvt p.
|
article
|
| 79 |
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
|
Hochman, Michael J
|
|
|
|
7 |
p. e523-e534
|
article
|
| 80 |
Newborn screening for sickle cell disease in Africa
|
Makoni, Munyaradzi
|
|
|
|
7 |
p. e476
|
article
|
| 81 |
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives
|
Wilkinson, Emma
|
|
|
|
7 |
p. e491
|
article
|
| 82 |
On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL
|
Ysebaert, Loic
|
|
2019
|
|
7 |
p. e343-e344
|
article
|
| 83 |
Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia
|
Ragni, Margaret V
|
|
|
|
7 |
p. e469-e470
|
article
|
| 84 |
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
|
van Moort, Iris
|
|
|
|
7 |
p. e492-e502
|
article
|
| 85 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
|
Soumerai, Jacob D
|
|
2019
|
|
7 |
p. e366-e374
|
article
|
| 86 |
Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study
|
Wiersum-Osselton, Johanna C
|
|
2019
|
|
7 |
p. e350-e358
|
article
|
| 87 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
|
Greil, Richard
|
|
2016
|
|
7 |
p. e317-e329
nvt p.
|
article
|
| 88 |
Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance
|
Venugopal, Sangeetha
|
|
|
|
7 |
p. e462-e463
|
article
|
| 89 |
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
|
Passamonti, Francesco
|
|
|
|
7 |
p. e480-e492
|
article
|
| 90 |
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial
|
Xue, Feng
|
|
|
|
7 |
p. e504-e513
|
article
|
| 91 |
Screening infants for sickle cell disease in sub-Saharan Africa: starting the journey to a sustainable model in primary care
|
Streetly, Allison
|
|
|
|
7 |
p. e503-e504
|
article
|
| 92 |
Selective inhibitors of nuclear export in aggressive B-cell lymphomas
|
Chiappella, Annalisa
|
|
|
|
7 |
p. e500-e501
|
article
|
| 93 |
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
|
Kalakonda, Nagesh
|
|
|
|
7 |
p. e511-e522
|
article
|
| 94 |
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
|
Andrés-Jensen, Liv
|
|
|
|
7 |
p. e513-e523
|
article
|
| 95 |
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
|
Song, Yuqin
|
|
|
|
7 |
p. e493-e503
|
article
|
| 96 |
Simplicity versus complexity: an existential dilemma as risk tools evolve
|
Khorana, Alok A
|
|
2018
|
|
7 |
p. e273-e274
|
article
|
| 97 |
Survival and new cancers with myeloproliferative neoplasms
|
Scherber, Robyn
|
|
2015
|
|
7 |
p. e272-e273
nvt p.
|
article
|
| 98 |
Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study
|
Frederiksen, Henrik
|
|
2015
|
|
7 |
p. e289-e296
nvt p.
|
article
|
| 99 |
Sustained prothrombotic changes in convalescent patients with COVID-19
|
von Meijenfeldt, Fien A
|
|
|
|
7 |
p. e475
|
article
|
| 100 |
20th Congress of European Hematology Association
|
Smith, Lan-Lan
|
|
2015
|
|
7 |
p. e274-e275
nvt p.
|
article
|
| 101 |
The complex genetic landscape of acute myeloid leukaemia
|
The Lancet Haematology,
|
|
2016
|
|
7 |
p. e301-
1 p.
|
article
|
| 102 |
The DESTINY of chronic myeloid leukeamia
|
Abruzzese, Elisabetta
|
|
2017
|
|
7 |
p. e303-e304
nvt p.
|
article
|
| 103 |
The dystopia of enforced childbirth
|
The Lancet Haematology,
|
|
|
|
7 |
p. e461
|
article
|
| 104 |
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
|
Cook, Gordon
|
|
2016
|
|
7 |
p. e340-e351
nvt p.
|
article
|
| 105 |
The essential role of randomised controlled trials
|
Marini, Bernard L
|
|
|
|
7 |
p. e486-e487
|
article
|
| 106 |
The evolving promise and potential of gene therapy
|
The Lancet Haematology,
|
|
|
|
7 |
p. e467
|
article
|
| 107 |
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm
|
Bakalov, Veli
|
|
|
|
7 |
p. e478-e479
|
article
|
| 108 |
The merits and limits of pooling data from nuclear power worker studies
|
Blettner, Maria
|
|
2015
|
|
7 |
p. e268-e269
nvt p.
|
article
|
| 109 |
The 52nd annual meeting of the American Society of Clinical Oncology
|
Smith, Lan-Lan
|
|
2016
|
|
7 |
p. e308-
1 p.
|
article
|
| 110 |
The need for better legislation for generic drug manufacturers
|
The Lancet Haematology,
|
|
2017
|
|
7 |
p. e302-
1 p.
|
article
|
| 111 |
Therapy de-escalation before stopping in chronic myeloid leukaemia
|
Mustjoki, Satu
|
|
2019
|
|
7 |
p. e345-e346
|
article
|
| 112 |
The real world of Waldenström's macroglobulinaemia
|
Treon, Steven P
|
|
2018
|
|
7 |
p. e275-e276
|
article
|
| 113 |
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?
|
Othman, Jad
|
|
|
|
7 |
p. e478-e479
|
article
|
| 114 |
Transparently report on the process of moving from evidence to recommendation
|
Lv, Meng
|
|
|
|
7 |
p. e472
|
article
|
| 115 |
Transparently report on the process of moving from evidence to recommendation – Authors' reply
|
Stemler, Jannik
|
|
|
|
7 |
p. e472-e473
|
article
|
| 116 |
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review
|
Buske, Christian
|
|
2018
|
|
7 |
p. e299-e309
|
article
|
| 117 |
Trials and tribulations: including women in cancer clinical research
|
Tang, Catherine
|
|
|
|
7 |
p. e477-e478
|
article
|
| 118 |
Unrelated cord blood transplantation for non-malignant diseases: every HLA allele counts
|
Scaradavou, Andromachi
|
|
2017
|
|
7 |
p. e307-e308
nvt p.
|
article
|
| 119 |
Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada
|
Liu, Ning
|
|
2018
|
|
7 |
p. e279-e288
|
article
|
| 120 |
Venous thromboembolism after induced abortion: the shorter the pregnancy, the lower the risk?
|
Middeldorp, Saskia
|
|
2018
|
|
7 |
p. e271-e272
|
article
|
Journal description